PetVivo's Surgeon Outreach Puts Spryng Adoption Against a Cash Test

Surgeon Outreach Puts the Clinical Story to a Sales Test

PetVivo's October 5 issuer post announced a Spryng exhibit at the ACVS Surgery Summit in Charlotte. Its September conference schedule dates the event October 8–10, 2026 and describes meetings with veterinary surgeons, practice owners and other clinicians. Spryng with OsteoCushion Technology is a veterinarian-administered joint device for animals with lameness and related joint conditions. A conference appearance creates access to a relevant professional audience; it does not establish a purchase order, customer conversion or incremental revenue.[1][2]

A July announcement links that outreach to a published Veterinary Record proof-of-concept study: 40 client-owned dogs received a single injection and were followed for 84 days. The issuer reports that 55% met at least a 25% improvement threshold on the modified Glasgow Composite Pain Scale. The company funded the study, the reported outcome measures were subjective, and the investigators called for further work using objective measures. Peer review and these preliminary observations support a clinician conversation; they do not establish broad long-term clinical effectiveness or the size of a commercial market.[3]

Product Revenue Is Growing From a Small Base

The June-quarter Form 10-Q reports $337,572 of revenue versus $297,500 a year earlier, an approximately 13.5% increase. Gross profit rose to $223,317 from $186,726. The filing says distributor Vedco accounted for approximately 70% of quarterly revenue, so wider practice adoption needs to show up as durable orders rather than simply a larger events calendar. A conference program is a route to awareness, not a substitute for disclosed sales and collections.[2][4]

The same quarter recorded a $1.61 million net loss and $965,779 of cash used in operations. Against that, the company held $122,633 in cash and reported a $372,293 working-capital deficit at June 30. These are dated filing figures, not estimates of its October balance. Management concluded that substantial doubt about its ability to continue as a going concern was not alleviated and discussed additional equity or debt funding. Financing terms and dilution remain central to a per-share assessment.[4]

Common shares issued and outstanding rose to 37,594,245 at June 30 from 35,849,919 at March 31, an approximately 4.9% increase over that period. Those counts are not a current float, and the filing discusses preferred shares, notes and other potential financing. A fresh share and cash reconciliation is essential before treating product-revenue growth as growth attributable to each common share.[4]

An OTC Quote With Limited Turnover Needs Context

Open PETV's chart on TradingView →

October 6 completed-session snapshot, Eastern time: the retrieved OTC daily feed shows a $0.74 close, a $0.74–$0.8251 quoted daily range and only 210 shares of reported volume. Simple averages of the last five and 20 daily closing marks are approximately $0.767 and $0.761, respectively. Sparse or zero-volume sessions in that same feed make technical levels less reliable than in a liquid market. A displayed close or chart print is not a guarantee of executable liquidity; no live spread or order-book depth was independently verified.[5]

The nearby $0.76–$0.77 closing-average zone and recent $0.80–$0.84 marks are historical reference points rather than price targets. More meaningful confirmation combines repeat Spryng orders, reported cash collections and sufficient market participation; financing on unfavorable terms or another weak cash-flow quarter undermines the thesis. Historical OTC prints are no substitute for current quotes and depth.[4][5]

Three Milestones Define the Next Update

• Post-conference evidence of new veterinary practice adoption, repeat purchases and distributor reorder demand.
• Further objective clinical data beyond the short-term, subjective proof-of-concept outcomes.
• A new SEC filing that reconciles cash, capital raised and the share count with reported revenue.

PETV is worth your attention for the measurable adoption test that follows this week's specialist outreach. The clinical publication and established sales channel give the company something concrete to put before surgeons.[2][3][4] The bullish case is repeat orders and better cash conversion; the counterweight is a going-concern disclosure, limited cash at the last reporting date and an exceptionally thin October 6 trading session.[4][5]

Research Sources

1. [1] October 5 issuer announcement: ACVS Surgery Summit participation
2. [2] September 16 issuer conference schedule: October 8–10 ACVS dates and product details
3. [3] July 14 issuer announcement: Veterinary Record clinical-study publication and limitations
4. [4] August 14 SEC Form 10-Q: June-quarter sales, cash, share count and going-concern note
5. [5] Yahoo Finance PETV daily history: October 6 OTC quote, volume and past closes

Research cutoff: October 6, 2026, after the regular session; financial data are from the quarter ended June 30, 2026. ACVS participation was announced but the October 8–10 event has not yet occurred. All figures are in U.S. dollars. The OTC quote and chart levels are dated references, not live transaction prices.